PA
AKRO

PharVision Advisers’s Akero Therapeutics AKRO Stock Holding History

PharVision Advisers’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,016
Closed -$238K – 680
2025
Q3 		$238K Buy
+5,016
New +$243K 0.13% 366

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PharVision Advisers's AKRO Position: Q4 2025 in Review

PharVision Advisers sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 5,016 shares — an estimated $238K sold.

PharVision Advisers first reported a position in AKRO in Q3 2025 and held it in 1 quarter. The position peaked at $238K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • PharVision Advisers reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 5,016 Akero Therapeutics shares in Q4 2025, an estimated $238K.
  • PharVision Advisers first reported a position in Akero Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Akero Therapeutics position peaked at $238K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.